Most researchers seeking out CJC-1295 in Polo soon discover that local retail options are all but absent from local stores. The key implication for Polo researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. This guide gives Polo researchers the framework to assess vendor quality rigorously and source high-purity CJC-1295 with confidence.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Polo researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors begins with the COA: locate the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. For Polo researchers evaluating new suppliers: a test quantity before committing to research volumes before committing to research quantities is standard practice in the community. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Polo
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade CJC-1295 without any obvious sign; always maintain cold chain and work with cold-shipped material. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
